Research Monkeys Face Euthanasia Following Suspension of Disease Studies: Report
:max_bytes(150000):strip_icc():format(jpeg)/rhesus-macaque-monkey-study-center-112525-2-2b7f396fa46f4e1fb742bd09fe6266f9.jpg)
The Centers for Disease Control and Prevention (CDC) has abruptly brought an end to primate research, impacting about 200 macaque monkeys who were previously involved in infectious disease studies. This decision, as reported by Science on November 21, marks a significant shift away from primate experiments used in various research areas, including HIV prevention. The monkeys, predominantly rhesus and pig-tailed macaques at CDC’s Atlanta facilities, are now awaiting either transfer to sanctuaries or euthanasia as a consequence of this change.
Sally Thompson-Iritani, overseeing the animal care program at the University of Washington, described this move as unprecedented. The termination of primate research has raised concerns among scientists, with Deborah Fuller, a HIV researcher and the director of the Washington National Primate Research Center, emphasizing the substantial setback this decision poses for the HIV field. The halting of primate studies was conveyed to U.S. researchers by Sam Beyda, the CDC’s deputy chief of staff and a former employee of the Department of Government Efficiency. Beyda was reportedly communicating the stance of Health and Human Services Secretary Robert F. Kennedy Jr., who is actively promoting a reduction in animal research through his Make America Healthy Again (MAHA) initiative.
The MAHA Commission, spearheaded by Kennedy, released a strategy featuring over 120 initiatives aimed at reshaping the approach to animal-based research, with a focus on transitioning towards human-based technologies. This strategy aligns with the administration’s priorities, as confirmed by the U.S. Department of Health and Human Services, which emphasised the commitment to ethical research practices and the minimization of laboratory animal usage. The transition plan for the affected research animals, however, remains undisclosed.
Whilst animal-welfare advocates have lauded the decision as a step towards eliminating ethically challenging and outdated experiments, concerns have been voiced by infectious-disease researchers. JoAnne Flynn, a prominent tuberculosis researcher, expressed apprehension over the potential interruption of critical work that may not be easily replaceable in systems closely resembling humans. The shift away from primate research has incited both praise and apprehension within the scientific community, reflecting the complex ethical considerations surrounding animal testing.
This unexpected development underscores the ongoing debate surrounding the ethical implications of animal research in scientific pursuits. The decision to terminate primate studies has ignited a discourse on the future of research methodologies, with calls for a balance between scientific progress and ethical considerations. As the scientific landscape continues to evolve, the fate of these research monkeys serves as a poignant reminder of the intricate ethical dilemmas inherent in biomedical research and the importance of prioritising animal welfare alongside scientific innovation.
In conclusion, the cessation of primate research at CDC facilities marks a significant shift in federal research policy, prompting both celebration and concern within the scientific community. This decision reflects a broader trend towards revisiting traditional research methodologies in favour of more ethically sound and scientifically robust approaches. As discussions surrounding the future of animal research unfold, the fate of these research monkeys remains uncertain, underscoring the complex interplay between scientific advancement and ethical considerations in modern biomedical research.